SG/PUT/NOVO-NORDISK B/750/0.1/21.03.25 | Market Closed - Boerse Frankfurt Warrants 11:43:51 03/07/2024 pm IST | ||
| 0.44 EUR | +15.79% |
|
| Current month | +2.70% | ||
| 1 month | -33.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 0.44 | +15.79% |
| 02/24/02 | 0.38 | +11.76% |
| 01/24/01 | 0.34 | -8.11% |
| 28/24/28 | 0.37 | 0.00% |
| 27/24/27 | 0.37 | +2.78% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 11:43 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7ZJJ |
| ISIN | DE000SW7ZJJ5 |
| Date issued | 20/03/2024 |
| Strike | 750 kr |
| Maturity | 21/03/2025 (261 Days) |
| Parity | 10 : 1 |
| Emission price | 0.88 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.01 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.02 € |
| Spread % | 4.35% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Warrants
- Warrant
